Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

2026 data Public-data reference. official source

Acne Vulgaris

Open-data reference.

68 US clinical trials · 2 currently recruiting

Active & Recent Trials

RECRUITING Early Phase 1 50 participants

Weekly Isotretinoin vs Tetracycline for Moderate Acne

Medical University of South Carolina

NCT06225570

RECRUITING Phase 1 18 participants

Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy

Stanford University

NCT05891795

ACTIVE NOT RECRUITING Phase 2 126 participants

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

Biofrontera

NCT05080764

ACTIVE NOT RECRUITING NA 50 participants

A Post Market Device Study for the Treatment of Acne

Cutera

NCT06469398

ACTIVE NOT RECRUITING Phase 1 30 participants

Lipidome and Microbiome Profile of Acne

University of California, Davis

NCT02713607

ACTIVE NOT RECRUITING NA 22 participants

Laser Treatment of Moderate to Severe Acne Vulgaris

Massachusetts General Hospital

NCT04466527

ACTIVE NOT RECRUITING Phase 4 10 participants

A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients

Sun Pharmaceutical Industries Limited

NCT06425900

COMPLETED Phase 3 1,034 participants

Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne

Almirall, S.A.

NCT02322866

COMPLETED Phase 1 1,000 participants

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris

Sun Pharmaceutical Industries

NCT06733402

COMPLETED Early Phase 1 978 participants

A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris

Sun Pharmaceutical Industries

NCT04797793

COMPLETED Early Phase 1 973 participants

A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris

Sun Pharmaceutical Industries

NCT04883736

COMPLETED Phase 1 762 participants

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris

Sun Pharmaceutical Industries

NCT06063473

COMPLETED Phase 3 759 participants

A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

Dermira

NCT03028363

COMPLETED Phase 3 748 participants

A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

Dermira

NCT03127956

COMPLETED Phase 3 744 participants

A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

Dermira

NCT03073486

COMPLETED Phase 3 742 participants

A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne

Stiefel, a GSK Company

NCT01017120

COMPLETED Phase 2 686 participants

Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel

Bausch Health Americas

NCT04892706

COMPLETED Phase 2 662 participants

Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris

Galderma R&D

NCT01320033

COMPLETED Phase 3 609 participants

An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris

Cassiopea SpA

NCT02682264

COMPLETED Phase 3 601 participants

P3 Long Term Safety Study of Once Daily SB204 in Acne

Novan

NCT02798120

COMPLETED Phase 2 591 participants

Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne

Stiefel, a GSK Company

NCT00713609

COMPLETED Phase 3 534 participants

Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.

Bayer

NCT00651469

COMPLETED Phase 2 509 participants

A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris

Braintree Laboratories

NCT02604680

COMPLETED Phase 3 490 participants

A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris

Almirall, S.A.

NCT02413346

COMPLETED Phase 3 434 participants

A Study of S6G5T3 in the Treatment of Acne Vulgaris

Sol-Gel Technologies

NCT03761810

COMPLETED Phase 2 420 participants

A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris

Dermira

NCT02431052

COMPLETED Phase 2 372 participants

Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris

AOBiome

NCT02832063

COMPLETED Phase 2 366 participants

A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

Dow Pharmaceutical Sciences

NCT00666900

COMPLETED Phase 2 364 participants

Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

Bausch Health Americas

NCT03003247

COMPLETED Phase 2 320 participants

A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris

Maruho Co.

NCT02571998

COMPLETED Phase 2 304 participants

Dose Range Study of CD5789 in Acne Vulgaris

Galderma R&D

NCT01616654

COMPLETED Phase 2 266 participants

Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne

DUSA Pharmaceuticals

NCT00706433

COMPLETED Phase 2 225 participants

BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris

BioPharmX

NCT02815332

COMPLETED 217 participants

Cultural Differences in Treatment Preferences and Perceptions of Acne

Northwestern University

NCT03192163

COMPLETED Phase 4 202 participants

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

Galderma R&D

NCT04451330

COMPLETED Phase 2 186 participants

A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris

AndroScience

NCT00525499

COMPLETED Phase 4 186 participants

A Treatment for Severe Inflammatory Acne Subjects

Galderma R&D

NCT02899000

COMPLETED Phase 3 183 participants

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Bausch Health Americas

NCT04214639

COMPLETED Phase 4 162 participants

Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face

Bausch Health Americas

NCT00952523

COMPLETED Phase 2 127 participants

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

XOMA (US)

NCT01498874

COMPLETED NA 125 participants

U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne

Stiefel, a GSK Company

NCT01446237

COMPLETED Phase 4 123 participants

AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation

Galderma R&D

NCT05089708

COMPLETED Phase 2 123 participants

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

Vanda Pharmaceuticals

NCT04856917

COMPLETED Phase 2 107 participants

Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)

Photocure

NCT00933543

COMPLETED NA 98 participants

Comparison Between Interactive Internet-based Education and Counseling for the Management of Acne With That of Internet-based Education Alone

University of California, Davis

NCT02031718

COMPLETED 76 participants

Long-term Follow-up Study of Subjects Who Completed Clinical Studies 755.1100_FA, 810.1100_FA, or 1064.1100_FA

Sienna Labs

NCT03039634

COMPLETED Phase 4 68 participants

A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris

Allergan

NCT02032407

COMPLETED Phase 1 60 participants

Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers

Novan

NCT01694810

COMPLETED Phase 1 56 participants

A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204

Novan

NCT02581072

COMPLETED Phase 4 51 participants

Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%

Galderma R&D

NCT00660985

COMPLETED Phase 2 50 participants

Infrared Non-Cutting Laser Therapy for Acne

University of Michigan

NCT00110643

COMPLETED NA 47 participants

A Clinical In-Use Evaluation to Assess the Tolerability and Efficacy of a Moisturizer on Acne Prone Skin

Kenvue Brands

NCT07224633

COMPLETED NA 45 participants

A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris

Johnson & Johnson Consumer Inc. (J&JCI)

NCT03128723

COMPLETED Phase 1 38 participants

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

Stiefel, a GSK Company

NCT01115322

COMPLETED Phase 4 36 participants

Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications

Stiefel, a GSK Company

NCT01015638

COMPLETED Phase 4 30 participants

Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris

Galderma R&D

NCT01209949

COMPLETED Phase 3 30 participants

Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne

Massachusetts General Hospital

NCT00722761

COMPLETED Phase 1 30 participants

A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris

Stiefel, a GSK Company

NCT01019603

COMPLETED Phase 2 27 participants

An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris

Cassiopea SpA

NCT02720627

COMPLETED Phase 4 26 participants

A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products

Bausch Health Americas

NCT01313728

COMPLETED Phase 4 26 participants

Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face

Bausch Health Americas

NCT00919191

COMPLETED Phase 4 26 participants

Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris

Wake Forest University

NCT01047189

COMPLETED Phase 4 21 participants

The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color

Derm Research, P

NCT03402893

COMPLETED Phase 2 20 participants

Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris

Photocure

NCT00673933

COMPLETED Phase 4 20 participants

Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color

Icahn School of Medicine at Mount Sinai

NCT03681470

COMPLETED NA 11 participants

Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris

Northwestern University

NCT00558831

COMPLETED Phase 1 10 participants

A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne

Naked Biome

NCT03450369

COMPLETED Phase 1 8 participants

Timolol for the Treatment of Acne and Rosacea

Johns Hopkins University

NCT02774590

Phase Distribution

PhaseTrial count
Early Phase 1 13
Phase 2 20
Phase 3 12
Phase 4 14

Top Sponsors

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Acne Vulgaris Trial Landscape

ClinicalTrials.gov lists 68 US studies indexed under Acne Vulgaris, and 2 of those are currently open to recruitment — roughly 3% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

The phase distribution for Acne Vulgaris shows 26 late-stage studies (Phase 3 and Phase 4 combined) alongside 33 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

Top sponsor activity for Acne Vulgaris is led by Galderma R&D with 7 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 68 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Acne Vulgaris?

PlainTrial tracks 68 US clinical trials for Acne Vulgaris, of which 2 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Acne Vulgaris?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →